Genomic Vision

Genomic Vision Intangible Assets

The Intangible Assets of Genomic Vision (GV.PA) as of Oct 23, 2026 is 37,000.00 EUR. In the previous year, Intangible Assets was 62,000.00 EUR — a change of -40.32% (lower).

Intangible Assets

37,000.00EUR

YoY

-40.32%

Last updated:

Intangible Assets of Genomic Vision is 2022 37,000.00 EUR. Intangible Assets of Genomic Vision was 2021 62,000.00 EUR. It decreases by -40.32% lower compared to the previous year.

The Genomic Vision Intangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Intangible Assets
Date
Intangible Assets
Jan 1, 2015
260,000.00 EUR
Jan 1, 2016
226,000.00 EUR
Jan 1, 2017
173,000.00 EUR
Jan 1, 2018
140,000.00 EUR
Jan 1, 2019
114,000.00 EUR
Jan 1, 2020
88,000.00 EUR
Jan 1, 2021
62,000.00 EUR
Jan 1, 2022
37,000.00 EUR
The Genomic Vision Intangible Assets history
YEARIntangible AssetsYoY
37,000.00EUR-40.32%
62,000.00EUR-29.55%
88,000.00EUR-22.81%
114,000.00EUR-18.57%
140,000.00EUR-19.08%
173,000.00EUR-23.45%
226,000.00EUR-13.08%
260,000.00EUR0.00%
260,000.00EUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genomic Vision Stock analysis

What does Genomic Vision do? Genomic Vision is a biotechnology company that was founded in 2004. It is based in Bagneux, France, and develops and markets innovative molecular diagnostic tools and services based on its patented platform technology. The company's business model is based on collaboration with large pharmaceutical and diagnostic companies to help accelerate their product development and improve their clinical outcomes. Genomic Vision specializes in genetic diagnostics and offers a platform for analyzing DNA structures, allowing for the detection and quantification of genetic changes associated with various diseases such as cancer, neurological disorders, and rare diseases. The company also offers customized solutions and services tailored to the specific needs of its customers. In addition, Genomic Vision licenses its technology and patents to pharmaceutical companies and other organizations. The company has already partnered with Hitachi High-Technologies in Japan to market its platform for cancer monitoring and to develop molecular tests for cancer and other diseases. Genomic Vision has also introduced products such as the FiberVision system for visualizing and analyzing DNA fibers and is working on a new diagnostic test for precise diagnosis of autism and other neurological disorders. The company aims to improve the diagnosis of genetic diseases and advance genomic research. With its patented technology and expertise in molecular diagnostics, Genomic Vision is well positioned to drive the development of new and innovative products. Overall, Genomic Vision is an emerging company focused on the development of molecular diagnostic tools and services, and has a solid foundation in DNA visualization and analysis. With its innovative products and services, the company is well positioned to drive the growth of the molecular diagnostics market and establish itself as a key player in the field. Genomic Vision is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genomic Vision stock

Intangible Assets of Genomic Vision is 37,000.00 EUR in 2022.

Intangible Assets of Genomic Vision changed from 62,000.00 EUR to 37,000.00 EUR, representing a -40.32% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Intangible Assets Genomic Vision since 2006 – with annual values, charts, and detailed analysis.

Intangible assets are non-physical assets such as patents, trademarks, copyrights, and software. They can be significant value drivers for technology and pharmaceutical companies.

Intangible Assets's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Intangible Assets's Genomic Vision historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Genomic Vision

All Key Metrics — Genomic Vision